bluebird bio, Inc.: insider trades · United States · SEC (Form 4)

About bluebird bio, Inc.

bluebird bio, Inc. is a U.S.-based biotechnology company historically listed on the NYSE/NASDAQ ecosystem, with BLUE trading on NASDAQ before the company’s delisting. It was incorporated in 1992 and later renamed bluebird bio in 2010. The company is headquartered in Somerville, Massachusetts, United States. bluebird bio built its franchise around ex vivo gene therapy, focusing on severe genetic and rare diseases where durable, potentially curative treatment options are limited. From a business perspective, bluebird bio’s core activities have centered on the development and commercialization of lentiviral gene therapies. Its commercial portfolio included three FDA-approved therapies in the United States: LYFGENIA for sickle cell disease, ZYNTEGLO for transfusion-dependent beta-thalassemia, and SKYSONA for cerebral adrenoleukodystrophy. These products define the company’s current value proposition: one-time, high-complexity therapies intended to address serious inherited disorders at their root cause. In practical terms, bluebird’s model combines clinical development, manufacturing expertise, patient identification, treatment-center activation, and long-term follow-up, all of which are essential in gene therapy. Historically, the company pursued a broader pipeline that also included oncology programs, but bluebird bio later spun off its oncology assets into 2seventy bio and refocused on severe genetic disease. That strategic narrowing improved the clarity of the investment case, but it also highlighted the execution challenges inherent in this segment: regulatory complexity, high manufacturing requirements, reimbursement negotiations, and the need to build trusted treatment-center networks. bluebird competes with other gene-therapy developers, rare-disease biotechs, and, in some indications, with established standards of care where available. Geographically, bluebird bio has been strongly U.S.-anchored, with corporate and operational functions concentrated in Massachusetts. The company previously maintained a European commercial presence, but it has pared that back materially over time, underscoring its shift toward the U.S. market. Its commercial footprint depends heavily on qualified treatment centers and payer access, making market adoption as important as scientific differentiation. A major recent development was the company’s acquisition by Carlyle and SK Capital, which closed on June 2, 2025. As a result, bluebird bio became a private company and its shares are no longer traded on any public exchange. For investors in France, Belgium, and Switzerland, this is an important context point: BLUE is now primarily relevant as a case study in gene-therapy commercialization, strategic M&A, and the risks and rewards of highly specialized biotech platforms rather than as an active listed equity opportunity.